Abstract

Novo-Nordisk A/S will report its quarterly results on August 5, 2026 Pre-Market; this preview outlines consensus forecasts for revenue, profitability and EPS, reviews the last quarter’s execution, and highlights what to watch across obesity and diabetes therapies, oral launches, capacity, pricing, and legal developments.

Market Forecast

Consensus for the current quarter points to revenue of 71.82 billion DKK, a year-over-year decline of 6.01%; EBIT is forecast at 29.55 billion DKK, down 12.23% year over year; adjusted EPS is estimated at 4.99 DKK, down 16.25% year over year. No company gross-margin or net-margin forecast is available in the collected datasets.

The main business is diabetes and obesity care, with expectations anchored in GLP-1 demand resilience and broader label usage; the segment’s growth lens this quarter will be shaped by production cadence and launch execution for newer dose forms. The most promising stream is the obesity franchise centered on semaglutide in both injectable and oral forms, with last quarter’s diabetes and obesity revenue at 91.36 billion DKK; year-over-year growth for this sub-portfolio was not disclosed in the collected materials.

Last Quarter Review

Novo-Nordisk A/S delivered prior-quarter revenue of 70.06 billion DKK with a gross profit margin of 85.96%, GAAP net profit attributable to the parent company of 48.56 billion DKK, a net profit margin of 50.15%, and adjusted EPS of 6.63 DKK, up 1.53% year over year.

A notable highlight was net profit’s quarter-on-quarter increase of 80.57%, reflecting mix and operating leverage dynamics. The main business remained highly concentrated in diabetes and obesity care at 91.36 billion DKK for the last reported period, supported by persistent GLP-1 uptake and dose optimization; detailed year-over-year growth by sub-segment was not disclosed.

Current Quarter Outlook

Core Diabetes and Obesity Care

The franchise’s near-term trajectory hinges on how effectively Novo-Nordisk A/S aligns supply with accelerating demand across its GLP-1 therapy set, particularly as new formulations and doses expand the addressable patient base. This quarter, investors will focus on whether shipment flows and fill rates in key markets keep pace with prescription trends while sustaining the attractive gross-margin profile indicated in the last report. The revenue estimate of 71.82 billion DKK implies a normalization from prior growth peaks, and margin cadence will likely depend on the production scale of higher-dose injectables and oral variants, which can carry differing cost curves during ramp-up.

Regulatory momentum is a core contributor to utilization patterns. In July, the European Commission granted marketing authorization for the Wegovy pill for adults with obesity or overweight accompanied by weight-related comorbidities, and also approved the Wegovy 7.2 mg injection in a single-dose pen. These milestones extend the therapeutic toolkit and are poised to support prescription growth in Europe as launches roll into additional countries during the second half, subject to supply availability. Meanwhile, heightened competitive marketing activity in the United States has prompted Novo-Nordisk A/S to seek judicial relief over allegedly misleading advertising by a rival; any interim rulings could affect the tone of market communications but are unlikely to alter underlying clinical value propositions in the short run.

A series of market updates underscores the expansion of clinical utility. In India, Wegovy injections received approval for treating metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis alongside lifestyle interventions, broadening the addressable pool in a major emerging market. As geographic authorizations accumulate, the balance between volume expansion and pricing will define realized revenue per patient. The company’s ability to navigate procurement dynamics and payer negotiations while scaling manufacturing to meet expanding indications will be crucial to sustaining both top-line consistency and robust profitability.

Obesity Treatments and Oral Semaglutide Launches

The obesity platform is set to be the company’s fastest-evolving revenue engine as new dose forms and indications drive adoption beyond early adopter populations. Reports indicate that, since its introduction earlier in the year, prescriptions for the oral Wegovy formulation surpassed three million, with more than 80% of new prescriptions going to GLP-1–naïve patients. This pattern suggests that oral therapy is expanding the market rather than simply shifting patients from established injectables. In practical terms, the oral option can improve access and adherence for patients who prefer pills over injections, potentially lifting persistence and overall treatment penetration in primary care.

The European approval of the Wegovy pill, together with the authorization of the 7.2 mg injection, offers a two-pronged approach: an easy-to-initiate daily oral regimen and a high-efficacy weekly injectable option. The coexistence of these forms can help clinicians tailor therapy to patient preferences, comorbidities, and weight-loss targets. For investors, the key questions this quarter include the speed of country-by-country launches, the structure of reimbursement and formulary positioning, and any observable patterns in switch versus naïve uptake as marketing and education campaigns progress.

Execution risks primarily relate to manufacturing throughput and the learning curve of scaling oral dosage production alongside high-dose injectables. Early-stage ramp costs can burden margins even as volumes rise, making the timing of cost absorption an important determinant of quarter-to-quarter EBIT variance. The estimate for adjusted EPS at 4.99 DKK, down 16.25% year over year, reflects the possibility that mix and ramp expenditures may temporarily soften earnings while the company builds durable capacity across drug substance and drug product steps. Observers will also watch whether procurement efforts with suppliers, reportedly focused on securing cost-competitive inputs, can support margin preservation without constraining supply.

Stock Price Drivers This Quarter

Revenue delivery versus the 71.82 billion DKK estimate is the first-order variable for the stock, followed by margin trajectory as signs emerge on production scale efficiencies for the Wegovy pill and the 7.2 mg injection. Price-disciplined growth, supported by expanding indications like MASH in India, will be assessed against any signals of payer pushback or regulatory pricing sensitivity in markets where obesity drug utilization is broadening. Investors will parse management’s commentary on unit growth, new-to-therapy starts, and inventory health in distributors and pharmacies to gauge second-half run-rate.

Legal developments in the United States around advertising claims could influence short-term sentiment, though the core of the equity story remains operational: execution on capacity, international rollouts, and the reliability of supply to serve ongoing demand. If preliminary injunctions or related rulings shift competitive messaging, the effect would likely be reflected more in perception than in immediate patient starts. A steady drumbeat of regulatory updates, such as European and UK decisions, has supported the narrative of widening clinical acceptance; translating these into sustained volumes with stable access will be central to the quarter’s interpretation.

Finally, investors will monitor the balance of growth investments and profitability. EBIT is forecast at 29.55 billion DKK, down 12.23% year over year, which frames expectations for ongoing spending on manufacturing scale-up, market access work, and launches. If the company articulates a clear pathway from short-term ramp costs to medium-term operating leverage—underpinned by robust gross margin levels like those reported last quarter—market participants may be more willing to look through near-term EPS pressure. Conversely, any indication that supply growth lags approval momentum could constrain revenue realization and dull the positive impact of recent authorizations.

Analyst Opinions

Across recent published rating actions, the dominant stance has been neutral. Jefferies reaffirmed Hold, most recently with a price target of 285 DKK; J.P. Morgan maintained Hold with a 250 DKK target; Deutsche Bank kept Hold with a 290 DKK target; and Barclays reiterated Hold with a 300 DKK target. Bernstein issued a Sell with a 175 DKK target, marking a minority bearish view. In terms of simple bullish-versus-bearish categorization, formal “Buy” initiations or upgrades were not observed in the collected period, while the lone directional call was bearish; however, the majority of institutions remained on the sidelines with Hold/Neutral views.

The prevailing neutral position centers on a consistent set of considerations: robust end-market demand for obesity and diabetes therapies, set against decelerating year-over-year growth as the base rises, alongside near-term margin considerations tied to scaling newer dose forms. These firms indicate that visibility into production throughput, the shape of launch curves for the Wegovy pill in Europe and other markets, and clarity on pricing and payer dynamics will be pivotal for upgrading conviction. Commentary also implies that sustained gross margins near last quarter’s reported level could be a supportive catalyst if accompanied by evidence that supply is reliably meeting demand in key geographies.

Well-known houses have also highlighted the pipeline and business development as potential swing factors. Announcements such as Novo-Nordisk A/S’s internal evaluation agreement related to a semaglutide implant for chronic weight management and milestone payments tied to partnered obesity assets suggest diversification within the obesity toolkit, which may incrementally de-risk the medium-term roadmap. At the same time, several neutral-rated institutions appear to await confirmation that incremental capacity and procurement initiatives translate into tangible improvements in unit availability and margin stability before leaning more positive.

Overall, the majority institutional stance is neutral heading into August 5, 2026 Pre-Market, with the balance of risk skewed to execution on supply, launch pacing for the oral and high-dose injectable portfolio, and the interplay of competitive messaging in the United States. A clean delivery against revenue of 71.82 billion DKK with resilient gross margin and a credible path to re-accelerate EPS beyond the current quarter’s estimated decline of 16.25% could be sufficient to shift the center of gravity toward a more constructive view, while shortfalls on any of these elements would likely reinforce the wait-and-see posture that characterizes current coverage.